Tesetaxel, Leading Oral Taxane In Clinical Development,
Receives FDA Designation As An Orphan Drug For Treatment Of Patients With Advanced Melanoma

Genta Incorporated (OTCBB: GNTA) announced today that the Company has received notice from the U.S. Food and Drug Administration (FDA) that tesetaxel, the Company’s oral taxane in clinical development, has been granted designation as an "Orphan[...]

Read The Full Article:
http://feeds.feedburner.com/~r/zampbioworld/iblI/~3/478091806/12313

Add to del.icio.us

Digg this

Post to Furl

Add to reddit

Add to myYahoo!